DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ANAGRELIDE HYDROCHLORIDE
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
All Clinical Trials for Anagrelide Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00175838 | Primary Thrombocythaemia 1 Trial | Active, not recruiting | Cambridge University Hospitals NHS Foundation Trust | N/A | 1997-07-01 | The purpose of this trial is to see if Hydroxyurea + aspirin is a better treatment than aspirin alone for Intermediate Risk Primary Thrombocythemia (PT) patients. |
| NCT00175838 | Primary Thrombocythaemia 1 Trial | Active, not recruiting | Institute of Cancer Research, United Kingdom | N/A | 1997-07-01 | The purpose of this trial is to see if Hydroxyurea + aspirin is a better treatment than aspirin alone for Intermediate Risk Primary Thrombocythemia (PT) patients. |
| NCT00175838 | Primary Thrombocythaemia 1 Trial | Active, not recruiting | University of Cambridge | N/A | 1997-07-01 | The purpose of this trial is to see if Hydroxyurea + aspirin is a better treatment than aspirin alone for Intermediate Risk Primary Thrombocythemia (PT) patients. |
| NCT00202644 | A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients | Completed | Shire | Phase 4 | 2006-01-01 | Essential thrombocythaemia is a disorder of bone marrow, which causes too many platelets to be produced. Platelets are small cells carried around in the blood, which help form blood clots. When patients have too many platelets, there is a risk of blood clots forming unnecessarily and excessive bleeding. The aim of this study is to gain additional information on the safety profile of Anagrelide (Xagrid(r)) and Hydroxyurea (also known as hydroxycarbamide). |
| NCT00413634 | The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) | Completed | Shire | Phase 2 | 2006-08-01 | Age related differences in response to a drug could arise from variation in pharmacokinetic (PK) and/or pharmacodynamic (PD) profiles between age groups. Whilst the efficacy and safety profile of anagrelide is well established through a well-documented clinical trial programme in patients of all ages, no formal studies have been carried out to investigate whether the PK profile of anagrelide and its metabolites is altered with age. This study is designed to allow comparisons to be made in terms of pharmacokinetics of anagrelide and its metabolites between elderly (≥ 65 years) and young (18-50 years) ET patients |
| NCT00648024 | Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2003-01-01 | The objective of this study was to investigate the bioequivalence of Mylan's anagrelide HCl 1 mg capsules to Shire US's Agrylin® 1 mg capsules following a single, oral 1 mg (1 x 1 mg) dose administration under fasting conditions. |
| NCT00648765 | Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2003-01-01 | The objective of this study was to investigate the bioequivalence of Mylan's anagrelide HCl 1 mg capsules to Shire US's Agrylin® 1 mg capsules following a single, oral 1 mg (1 x 1 mg) dose administration under fed conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Anagrelide Hydrochloride
Clinical Trial Locations for Anagrelide Hydrochloride
Trials by Country
Clinical Trial Progress for Anagrelide Hydrochloride
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Anagrelide Hydrochloride
Sponsor Name
